The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market ...

Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $52.76 which represents a slight increase of $0.64 or 1.23% from the prior close of $52.12. The stock opened at ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Big Pharma is in federal appeals court making the absurd argument that Medicare shouldn’t be able to negotiate drug prices, a ...

Bristol-Myers Squibb (BMY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners maintained a Hold rating on ...

Zenas BioPharma's obexelimab demonstrates strong clinical results, but financial uncertainties remain. See more on ZBIO stock and the current market outlook.